Research letter
Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series

https://doi.org/10.1016/j.jaad.2020.03.029Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (16)

  • Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study

    2022, Journal of Investigative Dermatology
    Citation Excerpt :

    For SJS (affecting <10% body surface area) and TEN (affecting >30% body surface area), there is no overlap syndrome for body surface area affecting 10‒30% body surface area. There also has been a unique bullous eruptive cirAE mimicking SJS and TEN, however with rapid response to immunosuppression and lower mortality (Molina et al., 2020). Because VigiBase does not have the clinical nuance to identify this morphology, this was unable to be studied.

View all citing articles on Scopus

Funding sources: None.

Conflicts of interest: None disclosed.

IRB approval status: This study was approved by the Partners Human Research Committee, the Institutional Review Board of Partners HealthCare (#2017P000501).

Reprints not available from the authors.

View full text